Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model
Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron dr...
Gespeichert in:
| Veröffentlicht in: | Molecular pharmaceutics 2023-02, Vol.20 (2), p.1025-1038 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1038 |
|---|---|
| container_issue | 2 |
| container_start_page | 1025 |
| container_title | Molecular pharmaceutics |
| container_volume | 20 |
| creator | Yang, Qiyao Dai, Qi Bao, Xiaoyan Zhou, Yi Lu, Yiying Zhong, Haiqing Wu, Linjie Guo, Yinglu Liu, Lihong Tan, Xin Xia, Yiyi Han, Min Wei, Qichun |
| description | Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron drug with cRGD peptide modification and paclitaxel (PTX) loaded in the hydrophobic core. The nanoparticles (cRGD-COS-CB/PTX) realized the boron delivery into tumor sites with an enhanced permeability and retention (EPR) effect and an active targeting effect achieved by the cRGD–integrin interaction on the surface of tumor cells. The uniform spherical nanoparticles can be selectively taken by hepatoma cells rather than normal hepatocytes. In vivo experiments showed that the nanoparticles had a targeting effect on tumor sites in both subcutaneous and orthotopic tumor models, which was an encouraging result for radiotherapy for liver cancer. To sum up, the nanoparticles we produced proved to be promising dual-functionalized nanoparticles for radiotherapy and chemotherapy. |
| doi_str_mv | 10.1021/acs.molpharmaceut.2c00771 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2758354988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2758354988</sourcerecordid><originalsourceid>FETCH-LOGICAL-a363t-36ca8b8a67610ddaf7bcaa69f32f78e1282eee676ba74ddf14135ce8ea9e974a3</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EouXxC8js2KTEdhI7S6jKQyp0U9bR1Jm0rpI42A4Sf0-qlkrsWM1Ic--dmUPILYsnLObsHrSfNLbuNuAa0NiHCddxLCU7IWOWJiJSIuenx14lI3Lh_TaOeZJycU5GIkslk3k6Jm72BXUPwdiW2ooCXfaNddES3BqDadd0UZu19aD1sMyUSN-htf7bB2yoaenj-3RJByu0dOHCxgbbGU1fsINgNdZ1X4OjU3DatLYB-mZLrK_IWQW1x-tDvSQfT7Pl9CWaL55fpw_zCEQmQiQyDWqlIJMZi8sSKrnSAFleCV5JhYwrjojDdAUyKcuKJUykGhVCjrlMQFySu31u5-xnjz4UjfG7o6BF2_uCy1SJNMmVGqT5Xqqd9d5hVXTONOC-CxYXO-TFgLz4g7w4IB-8N4c1_arB8uj8ZTwI0r1gl7G1vWuHr_8R_AONYpe4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2758354988</pqid></control><display><type>article</type><title>Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model</title><source>ACS Publications</source><source>MEDLINE</source><creator>Yang, Qiyao ; Dai, Qi ; Bao, Xiaoyan ; Zhou, Yi ; Lu, Yiying ; Zhong, Haiqing ; Wu, Linjie ; Guo, Yinglu ; Liu, Lihong ; Tan, Xin ; Xia, Yiyi ; Han, Min ; Wei, Qichun</creator><creatorcontrib>Yang, Qiyao ; Dai, Qi ; Bao, Xiaoyan ; Zhou, Yi ; Lu, Yiying ; Zhong, Haiqing ; Wu, Linjie ; Guo, Yinglu ; Liu, Lihong ; Tan, Xin ; Xia, Yiyi ; Han, Min ; Wei, Qichun</creatorcontrib><description>Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron drug with cRGD peptide modification and paclitaxel (PTX) loaded in the hydrophobic core. The nanoparticles (cRGD-COS-CB/PTX) realized the boron delivery into tumor sites with an enhanced permeability and retention (EPR) effect and an active targeting effect achieved by the cRGD–integrin interaction on the surface of tumor cells. The uniform spherical nanoparticles can be selectively taken by hepatoma cells rather than normal hepatocytes. In vivo experiments showed that the nanoparticles had a targeting effect on tumor sites in both subcutaneous and orthotopic tumor models, which was an encouraging result for radiotherapy for liver cancer. To sum up, the nanoparticles we produced proved to be promising dual-functionalized nanoparticles for radiotherapy and chemotherapy.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.2c00771</identifier><identifier>PMID: 36571795</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Boranes ; Boron ; Boron Neutron Capture Therapy - methods ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - radiotherapy ; Cell Line, Tumor ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - radiotherapy ; Oligosaccharides</subject><ispartof>Molecular pharmaceutics, 2023-02, Vol.20 (2), p.1025-1038</ispartof><rights>2022 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a363t-36ca8b8a67610ddaf7bcaa69f32f78e1282eee676ba74ddf14135ce8ea9e974a3</citedby><cites>FETCH-LOGICAL-a363t-36ca8b8a67610ddaf7bcaa69f32f78e1282eee676ba74ddf14135ce8ea9e974a3</cites><orcidid>0000-0001-9373-8466</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00771$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.2c00771$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36571795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Qiyao</creatorcontrib><creatorcontrib>Dai, Qi</creatorcontrib><creatorcontrib>Bao, Xiaoyan</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Lu, Yiying</creatorcontrib><creatorcontrib>Zhong, Haiqing</creatorcontrib><creatorcontrib>Wu, Linjie</creatorcontrib><creatorcontrib>Guo, Yinglu</creatorcontrib><creatorcontrib>Liu, Lihong</creatorcontrib><creatorcontrib>Tan, Xin</creatorcontrib><creatorcontrib>Xia, Yiyi</creatorcontrib><creatorcontrib>Han, Min</creatorcontrib><creatorcontrib>Wei, Qichun</creatorcontrib><title>Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron drug with cRGD peptide modification and paclitaxel (PTX) loaded in the hydrophobic core. The nanoparticles (cRGD-COS-CB/PTX) realized the boron delivery into tumor sites with an enhanced permeability and retention (EPR) effect and an active targeting effect achieved by the cRGD–integrin interaction on the surface of tumor cells. The uniform spherical nanoparticles can be selectively taken by hepatoma cells rather than normal hepatocytes. In vivo experiments showed that the nanoparticles had a targeting effect on tumor sites in both subcutaneous and orthotopic tumor models, which was an encouraging result for radiotherapy for liver cancer. To sum up, the nanoparticles we produced proved to be promising dual-functionalized nanoparticles for radiotherapy and chemotherapy.</description><subject>Boranes</subject><subject>Boron</subject><subject>Boron Neutron Capture Therapy - methods</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - radiotherapy</subject><subject>Cell Line, Tumor</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - radiotherapy</subject><subject>Oligosaccharides</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0EouXxC8js2KTEdhI7S6jKQyp0U9bR1Jm0rpI42A4Sf0-qlkrsWM1Ic--dmUPILYsnLObsHrSfNLbuNuAa0NiHCddxLCU7IWOWJiJSIuenx14lI3Lh_TaOeZJycU5GIkslk3k6Jm72BXUPwdiW2ooCXfaNddES3BqDadd0UZu19aD1sMyUSN-htf7bB2yoaenj-3RJByu0dOHCxgbbGU1fsINgNdZ1X4OjU3DatLYB-mZLrK_IWQW1x-tDvSQfT7Pl9CWaL55fpw_zCEQmQiQyDWqlIJMZi8sSKrnSAFleCV5JhYwrjojDdAUyKcuKJUykGhVCjrlMQFySu31u5-xnjz4UjfG7o6BF2_uCy1SJNMmVGqT5Xqqd9d5hVXTONOC-CxYXO-TFgLz4g7w4IB-8N4c1_arB8uj8ZTwI0r1gl7G1vWuHr_8R_AONYpe4</recordid><startdate>20230206</startdate><enddate>20230206</enddate><creator>Yang, Qiyao</creator><creator>Dai, Qi</creator><creator>Bao, Xiaoyan</creator><creator>Zhou, Yi</creator><creator>Lu, Yiying</creator><creator>Zhong, Haiqing</creator><creator>Wu, Linjie</creator><creator>Guo, Yinglu</creator><creator>Liu, Lihong</creator><creator>Tan, Xin</creator><creator>Xia, Yiyi</creator><creator>Han, Min</creator><creator>Wei, Qichun</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9373-8466</orcidid></search><sort><creationdate>20230206</creationdate><title>Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model</title><author>Yang, Qiyao ; Dai, Qi ; Bao, Xiaoyan ; Zhou, Yi ; Lu, Yiying ; Zhong, Haiqing ; Wu, Linjie ; Guo, Yinglu ; Liu, Lihong ; Tan, Xin ; Xia, Yiyi ; Han, Min ; Wei, Qichun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a363t-36ca8b8a67610ddaf7bcaa69f32f78e1282eee676ba74ddf14135ce8ea9e974a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Boranes</topic><topic>Boron</topic><topic>Boron Neutron Capture Therapy - methods</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - radiotherapy</topic><topic>Cell Line, Tumor</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - radiotherapy</topic><topic>Oligosaccharides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Qiyao</creatorcontrib><creatorcontrib>Dai, Qi</creatorcontrib><creatorcontrib>Bao, Xiaoyan</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Lu, Yiying</creatorcontrib><creatorcontrib>Zhong, Haiqing</creatorcontrib><creatorcontrib>Wu, Linjie</creatorcontrib><creatorcontrib>Guo, Yinglu</creatorcontrib><creatorcontrib>Liu, Lihong</creatorcontrib><creatorcontrib>Tan, Xin</creatorcontrib><creatorcontrib>Xia, Yiyi</creatorcontrib><creatorcontrib>Han, Min</creatorcontrib><creatorcontrib>Wei, Qichun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Qiyao</au><au>Dai, Qi</au><au>Bao, Xiaoyan</au><au>Zhou, Yi</au><au>Lu, Yiying</au><au>Zhong, Haiqing</au><au>Wu, Linjie</au><au>Guo, Yinglu</au><au>Liu, Lihong</au><au>Tan, Xin</au><au>Xia, Yiyi</au><au>Han, Min</au><au>Wei, Qichun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2023-02-06</date><risdate>2023</risdate><volume>20</volume><issue>2</issue><spage>1025</spage><epage>1038</epage><pages>1025-1038</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron drug with cRGD peptide modification and paclitaxel (PTX) loaded in the hydrophobic core. The nanoparticles (cRGD-COS-CB/PTX) realized the boron delivery into tumor sites with an enhanced permeability and retention (EPR) effect and an active targeting effect achieved by the cRGD–integrin interaction on the surface of tumor cells. The uniform spherical nanoparticles can be selectively taken by hepatoma cells rather than normal hepatocytes. In vivo experiments showed that the nanoparticles had a targeting effect on tumor sites in both subcutaneous and orthotopic tumor models, which was an encouraging result for radiotherapy for liver cancer. To sum up, the nanoparticles we produced proved to be promising dual-functionalized nanoparticles for radiotherapy and chemotherapy.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>36571795</pmid><doi>10.1021/acs.molpharmaceut.2c00771</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-9373-8466</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1543-8384 |
| ispartof | Molecular pharmaceutics, 2023-02, Vol.20 (2), p.1025-1038 |
| issn | 1543-8384 1543-8392 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2758354988 |
| source | ACS Publications; MEDLINE |
| subjects | Boranes Boron Boron Neutron Capture Therapy - methods Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - radiotherapy Cell Line, Tumor Humans Liver Neoplasms - drug therapy Liver Neoplasms - radiotherapy Oligosaccharides |
| title | Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A48%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20a%20Tumor-Targeting%20Oligosaccharide%20Nanosystem%20in%20BNCT%20on%20an%20Orthotopic%20Hepatocellular%20Carcinoma%20Model&rft.jtitle=Molecular%20pharmaceutics&rft.au=Yang,%20Qiyao&rft.date=2023-02-06&rft.volume=20&rft.issue=2&rft.spage=1025&rft.epage=1038&rft.pages=1025-1038&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.2c00771&rft_dat=%3Cproquest_cross%3E2758354988%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2758354988&rft_id=info:pmid/36571795&rfr_iscdi=true |